CATX · Perspective Therapeutics Inc
United States · RS rating 10 · As of 2026-10-14
| Price | 2.24 USD |
|---|---|
| 1-day change | -1.3% |
| RS rating (overall / 1M / 3M / 12M) | 10 / 13 / 15 / 13 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 17 / 13 / 19 |
| Industry group (rank) | Medical-Ethical Drugs (91) |
| EPS growth Q/Q | +12.0% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +60.4% |
| Market cap (USD) | $514.2M |